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Introdução e Objetivos: O objetivo deste estudo foi determinar se os 
comprimidos com ranhura de divisão, comercializados em Portugal, apresentam uma 
quebra deficiente e se tal se constitui um obstáculo, nomeadamente para a população 
idosa. Outro objetivo foi avaliar a conformidade deste tipo de comprimidos com os 
requisitos regulamentares e identificar possíveis incoerências relacionadas com a 
rotulagem.  
Métodos: Foi realizado um estudo com 47 voluntários, de modo a avaliar se a 
perda de massa durante a subdivisão de comprimidos é significativa e para quantificar 
a facilidade de quebra de comprimidos para os utentes. Foram incluídos comprimidos 
“padrão” em cada conjunto dado aos voluntários. Esperava-se que os utentes 
manifestassem o grau de dificuldade de quebra de modo a ser detetada a quota parte 
atribuivel a cada utente em si. Antes dos conjuntos serem cedidos aos utentes foram 
avaliados em laboratório em termos de uniformidade da massa, bem como da 
resistência ao esmagamento (dureza dos comprimidos) e as dimensões dos mesmos. 
Esperava-se que estes testes apresentassem resultados relativamente ao desvio de 
massa e que os mesmos, em conjunto com as características dos comprimidos 
ajudassem a prever o comportamento dos mesmos no estudo com os voluntários.  
Resultados: Em cerca de 10% das observações verificou-se a incapacidade 
dos voluntários em quebrar os comprimidos ou a sua fragmentação em mais do que as 
duas metades esperadas. Em cerca de metade das avaliações os utentes classificaram 
os comprimidos como muito fáceis de quebrar. No entanto, num quinto das 
observações os utentes avaliaram os comprimidos como difíceis ou muito difíceis de 
quebrar, bem como os casos em que o utente não conseguiu partir o comprimido.  
Conclusão: A implementação de requisitos regulamentares é de extrema 
importância, pois critérios mais rigorosos permitirão um menor número de não 
conformidades e, portanto, maior segurança para o utente em relação ao uso de 
comprimidos com ranhura de quebra. O uso de modelos de previsão pode ser um 
recurso útil que permita determinar quais os parâmetros físicos e farmacotécnicos que 
devem ser otimizados de modo a ser obtida uma subdivisão mais precisa e adequada 
de comprimidos ranhurados.   
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Introduction & Aims: The aim of this project was to determine if the tablets bearing 
a break or score line, marketed in Portugal, present inaccurate subdivision, especially 
regarding the elderly population. Another aim was to assess the compliance 
with regulatory requirements of such products, and to target possible  issues regarding 
labelling.  
 
Methods: A study comprehending  47 volunteers was performed, to evaluate if mass 
loss during tablet subdivision is significant and to quantify the ease of subdivision of 
tablets for the patients. Standard tablets that would be considered either too hard or 
two easy to break were included in each set given to the volunteers, in order to detect 
possible patient-related issues. Previously to this study, the mass uniformity of the 
provided tablets was assessed, as well as the resistance to crushing (tablet hardness) 
and measurements of the tablets. It was expected that assessments presented mass 
deviation results and tablet characteristics that would help to predict the behavior of 
the tablets in the study with the volunteers, as well as an established prediction model. 
 
Results: About 10% of the observations reflect either the inability of the volunteers to 
break the tablets or the splitting of tablets in more fragments than the two expected 
halves. Around half of the observations correspond to situations in which the patients 
classified the tablets as very easy to break. However a fifth of the observations 
represent situations where the patients found the tablets hard or very hard  to break as 
well as cases where the patient was not able to break the tablet.  
 
Conclusion: Implementation of regulatory requirements have a particular importance 
since more strict criteria would allow less non conformities, and therefore more safety 
for the patient regarding the use of scored tablets. The use of prediction models can be 
used as an asset in order to determine which tablet physical and pharmacotechnic 
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1 Introduction 
1.1 Usage of scores to break tablets 
1.1.1 The aim of tablet score lines 
 
Patients split tablet for various reasons, namely for adjusting the dosage (1) because 
the dosage that they need is not marketed (2) or if the dosage is marketed but it 
is unavailable. Splitting tablets is also a solution if the tablet is too big for the 
patient to swallow so they break it in half to ease the swallowing of the tablet. 
(3) There is also a third cause, when two tablet strengths have the same cost, 
then splitting leads to the cost of treatment becoming cheaper. (4)(5) What can 
also occur regarding the price is that a higher strength can represent a larger 
reimbursement.  (6) 
Tablet subdivision allows dose flexibility across specific population – as the 
paediatric and the elderly. (3) For example, in case of need to titration or to 
reduce side effects. (2) (5) 
 
1.1.2 Issues of tablet subdivision 
 
When a patient breaks a tablet in two halves, they can break unevenly. Also, the 
patient can experience cases of mass loss, them being crumbling and 
powdering. (2) (7) This has a particular impact in drugs with a short therapeutic 
margin, due to mass loss. (2) Patients relate the inaccurate subdivision of 
tablets with quality issues, leading to non compliance to medication by the 
patient. (5) 
Another problem with subdivision is that it entails that the drug is removed from the 
foil blister, therefore exposing it to air and humidity, increasing the rate of 
degradation, an in consequence adverse effects may appear because of these 
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degradation products. Thus it should be taken in account for how long are the 
tablets left split. (2)  
Another unwanted case that can occur is that if a tablet which is coated with the 
purpose of masking the unpleasant taste of the drug that it contains, than the 
flavour related masking effect is disrupted because of splitting it. (2) Also 
regarding coating, Toxicity effects can occur if the enteric coating is disrupted, 
due to the drug included in such tablet being irritant. This can also happen with 
antineoplastic drugs, since they can lead to intoxication.  (8) 
Apart from the issues with scored tablets, an even greater problem is that tablets that 
are not scored are also subdivided, sometimes advised from the prescriber, 
reflecting lack of information by healthcare professionals. (6) 
 
1.1.3 Causes to uneven splitability and mass loss 
 
1.1.3.1 Related to the patient 
 
There are a few patient’s characteristics that can handicap tablet splitability - specially 
because of age progression - namely visual acuity, dexterity and strenght. (4) 
Some diseases that the elderly present more commonly as Parkinson’s disease 
and arthritis, can also influence the splitability (7), since they reduce grip 
strength and cause impaired manual dexterity. (2)  
Even though there are various methods for tablet splitting -  namely the usage of 
hands, knives or tablet cutters - even the usage of tablet cutters imply some 
level of dexterity. (2) So outcomes of tablet scoring depend not only on the user 
but also on the device. (5) 
There also might be some compliance issues regarding the elderly, who sometimes 
skip or double the doses not to break the tablets. Also sometimes they retain 
broken halves that were not used, thus it is advised to instruct patients about the 
appropriate way to store tablet halves. (2) 
It is also reported that sometimes patients break tablets by their own choice,  which 
can lead to problems if they are not well informed. (6) 
1.1.3.2 Related to tablet characteristics 
 
With or without score marks, the size, the shape (4)(7) and the hardness (3) of a tablet 
can affect the accuracy of cutting it in half.  If the tablet is too small, has an 
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irregular shape or is only scored in one side, it can also lead to inaccuracy of 
splitting.  (2)   
A study that aimed to develop a model to predict the ease of subdivision based on 
physical characteristics of tablets established which of these characteristics 
would be crucial for either round or oblong tablets. For both types of tablets, 
the diameter and the resistance to crushing have significance. For oblong 
tablets also the ratio between diameter and width has importance as does the 
depth of the score line. In the case of round tablets it also matters if they are 
scored in either only one side of the tablet or both sides and if the tablet is 
either flat or biconvex. (9) 
Techniques as compress molding and multi-layered tablets improve tablet scoring 
accuracy. (3) Pressure sensitive tablets are also an alternative that aid the 
subdivision.  (7) An example of a pressure sensitive tablet and the proper way 
to break it is shown in Figure 1. (10) 
 
 
Figure 1. Pressure sensitive tablet 
Retrieved from (10) 
 
1.2 Regulatory requirements and Guidance documents 
 
1.2.1 The European Pharmacopeia (Ph. Eur. ) approach  
 
The Ph. Eur.  established for the first time Pharmacopeial standards regarding 
tablet subdivision, in 2002. Since then these standards have been updated. (5) 
In the Ph. Eur.  there is a section in the “Tablets” monography, which refers to 
the “Subdivision of Tablets”. In those paragraphs, it is said that the competent 
authority must authorize the subdivision if the purpose of it is to obtain doses 
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accordingly to posology. That authorization must be based on an assessment of mass 
uniformity, which takes place in the developing phase. A total of thirty tablets is split 
by hand. From each whole tablet only one part is used to calculate the deviation, in 
comparison to the average mass. This value should be between 85% and 115% of the 
average mass. Not more than one tablet should position outside these limits, and no 
tablet can be outside the limits 75% to 125%. (11) This assessment should either 
occur during product development or for validation purposes. (12) 
 
1.2.2 Stimuli article from the United States Pharmacopeial Convention 
 
 In this article, published in 2009, standards for the United States Pharmacopeia 
(USP) are proposed, regarding the subdivision of tablets. This proposal is based on 
research studies done by other entities and the “Tablets” monograph from the Ph. 
Eur.. It is also recognised, based on one of the referred studies, that three quality 
attributes can define the performance of score lines. These attributes are examined in 
the document.  The first is “accuracy of subdivision”, considered the most important 
out of the three. To establish this standard the proponents adopted the testing and 
limits of the Ph. Eur., although not adopting the same spectrum of application. This 
dissimilarity is based on the facts that in this document it is not supported that all 
scored tablets should be tested, but only those whose purpose of scoring is to adjust 
the dose. In addition, it is defended that the standards should not rely on posology 
schemes also because it is subjective and because that creates omission in case of off-
label usage.  The second attribute is the “loss of mass”, and since no limit for this 
matter was yet established it is proposed a limit of  ≤ 3% mean loss of mass upon 
subdivision.  The third and last one is the “ease of breaking” or “ease of subdivision”, 
which is described to be independent of the other two quality attributes. It was 
considered that the USP should adopt a standard for this matter, and to do so it should 
be done with “real world testing”. However, it would not be workable for batch-to-
batch testing.  Alternatively,  it is said that at least every batch should be assessed on 
these attributes, and that they should comply with the established standards. (5) 
 
1.2.3 FDA approach to tablet scoring 
 
On 2011, FDA published the draft of a document “Guidance For Industry – 
Tablet Scoring: Nomenclature, Labelling, and Data for Evaluation”, that reflects 
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recommendations of the agency, not only so that new applications of scored tablets 
are more likely to be approved but also in the matter of labelling such products. These 
apply either to reference drugs and generic drugs since they should have consistent 
scoring. This has special relevancy if the aim of the score line is to adjust the dose. 
For instance, for the patient to be able to switch between brands without 
compromising the quantity of the active substance present in each halve, the generic 
should have a score line if the RLD has one. Also, it should not have a score mark if 
the RLD does not, because that would generate an imbalanced competition on the 
market.  Furthermore, it mentions safety issues regarding the content of each halve if 
a tablet either was not tested for tablet subdivision or if it does not have a score line at 
all, especially because tablet subdivision has become a recurrent practice.  
This guidance also introduces the concept of “functional scoring”. The term is 
applied if the tablet complies with established criteria, therefore communicating that 
information to healthcare providers. For that reason, it is recommended that 
manufacturers update the prescribing information where it is mandatory to state that 
the product is scored to it having a “functional scoring”. Not only is there a concern 
with the inclusion of a reference to scoring, but also it is mentioned that when tablets 
do not meet the established criteria there should be no referral of a score line or 
similar words, e.g. bisected, nor should this feature be present in the tablet.  
Moreover, the guidance mentions cases when tablets should not have a score 
line, namely: the obtainment of under therapeutic range doses when a tablet is 
subdivided; drug exposure with risk for the person who is breaking it; and disruption 
of modified release systems. There is also a concern when halves of tablets are stored 
in containers, so stability in specific conditions should be tested. Finally, it is 
suggested that tablet halves should have to meet the same criteria as a whole tablet 
with the same strength. 
Apart from Modified Release tablets for which additional criteria regarding 
dissolution is added, there are three assessments that should be done in solid oral 
dosage forms, namely in the split tablets: weight variation/content uniformity (as 
described in the USP <905>, “Uniformity of Dosage Units”; tablet splitability (at both 
ends of the proposed hardness range) regarding mass loss and friability; and 
dissolution assays. It is also suggested that these assessments are done not only during 
the Pharmaceutical Development but also with stability batches and scale-up. (1) 
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1.2.4 The United States Pharmacopeia approach 
 
The USP <705> (“Quality Atributes of Tablets Labelled as Having a 
Functional Score”) includes three tests to which split portions of functional scored 
tablets should comply to.  However only the first test, “Splitting Tablets with 
Functional Scoring” assesses the accuracy of subdivision. This test has a quite 
different approach from the Ph. Eur. “Subdivision of tablets” testing, depicted by the 
following aspects. To begin with, both split fragments are analysed. Another reason 
why they differ is because the mass deviation is in comparison to the expected weight 
of each fragment (obtained dividing the weight of a whole tablet), instead of being in 
comparison to an average mass. Thirdly, this obtained deviation should be located 
between the limits of 75% and 125%, the acceptance criteria being that not more than 
two out of the thirty tablets fail to comply with the test. 
Other relevant aspects are mentioned. First, that the subdivision is done using 
only hands, with no “mechanical assistance”. It is also expressed a concern regarding 
storage conditions and  period for the split tablets. And finally, regarding labelling, it 
is mentioned that the intended dose after subdivision should be stated in such 
documents. (13) 
 
1.2.5 WHO Prequalification of Medicines Programme Guidelines 
 
In the context of this programme, manufacturers can submit their Expression of 
Interest relatively to products for which subdivision of the tablet is required. 
Therefore, there are Guidelines regarding quality that include requirements for the 
acceptance of functionally scored tablets. For example, it is required that a dose 
uniformity testing for the split tablets (mass uniformity or content uniformity for 
special cases) is done - in both fragments of at least ten tablets - and that information 
about the method is provided, including detailed results  -  the mean, the deviation and 
individual values. The testing should also mimic the way the consumer would 
subdivide the tablet.  
Concerning the labelling, namely the Summary of Product Characteristics 
(SmPC) and the package leaflet, the presence of a score and its intent should be 
referenced. (14) This is illustrated in another prequalification guidance document, the  
SmPC template, where three standard quotes are provided:  “The scoreline is only to 
facilitate breaking for ease of swallowing and not to divide into equal doses.”, “The 
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tablet can be divided into equal halves.” and “The tablet should not be divided.” (15) 
1.2.6 WHO Revision of Monograph on Tablets  
 
In this document, critical steps of the manufacturing of tablets are described. In 
the case of scored tablets, which purpose is to subdivide into smaller doses, it is 
reiterated that during the development the effectiveness of break marks should be 
assessed. The described test is referred to mass uniformity and is based on the one 
described above by the Ph. Eur..  
There is also a concern about labelling, implying that information about the 
storage of spilt tablets that are not intended to be taken right before the splitting, 
should be present in the label, as well as the conditions in which they should be 
stored.  (16) 
 
1.2.7 The European Medicines Agency approach to paediatrics and the 
elderly population 
 
In two different moments, The European Medicines Agency (EMA) has 
expressed concern about two especially sensitive populations, regarding 
pharmaceutical development - the paediatric and the older population – as they 
sometimes have special modifications in oral intake of drugs. (17) (18) 
 First, in 2013 EMA published a Guideline regarding pharmaceutical 
development of medicines for paediatric use, which includes the case of scored 
tablets. It is denoted that the intended function of the score mark should be stated in 
the SmPC or the Patient Information Leaflet (PIL) and the suitability and ease of 
breaking should be demonstrated. It should also be stated if certain characteristics as 
being a modified release tablet nullify the splitting. In this specific population, it is 
sometimes needed to add either food or drinks with the medication, so it is considered 
important to provide information about compatibility with suggested vehicles. (17) 
Then, in 2017 EMA published a reflection paper regarding pharmaceutical 
development of medicines for use in older population, also including the case of 
scored tablets.  In the case of this population, some modifications should be made to 
either ease the intake or to lower the dose. Some examples of very relevant issues are 
brought up in this document. Regarding labelling, even though the scored tablets 
function is stated either in the SmPC or the PIL, sometimes the information on the 
physical leaflet is not yet up to date. Secondly, that when there are no alternatives, 
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off-label subdivision is sometimes recommended by healthcare professionals. Also, 
the discrepancy of the function of a score mark between brands is mentioned and  
finally the case where it is stated a tablet should not be subdivided despite it 
presenting a suggestive break mark. To resolve these issues, it is encouraged that all 
scored tablets regardless of its function break into equal parts and it is also suggested 
that companies started characterising the patient who would be comfortable breaking 
their tablets. Other suggested options are to the company to improve the breakability 





The aim of this dissertation was to determine if medicines marketed in Portugal 
were in conformity with the regulatory requirements regarding tablets subdivision. To 
do so a study with volunteers was performed. The objectives of this study were: to 
evaluate if mass loss during tablet subdivision is significant; and to quantify the ease 
of subdivision of tablets for the patient.  
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3 Materials and Methods 
 
One of the aims of this research project was to assess the regulatory compliance 
of the subdivision of tablets bearing a break or score line.  This assessment was 
performed by analyzing the result of breaking or splitting tablets, performed 
by volunteers, of a sample of medicines marketed in Portugal.  
For that purpose, it was necessary to evaluate if mass loss during the splitting 
process was significant and in what kind of extension was this act a struggle for the 




The starting point of the present work was to identify medicines marketed in 
Portugal bearing score lines. Since this research aimed to identify potentially 
problematic medicines regarding its correct breakability for the elderly patients, the 
chosen tablets contained drugs commonly used to treat chronic diseases. The database 
used was Infomed (19), from INFARMED. The Summary of Product Characteristics 
from each of the marketed chosen drugs dosage was consulted. The purpose was to 
find out which of the tablets had a score line and if so, what its purpose was. Even 
though some did not have that information, in the majority of the cases it was 
described that the score line had one of the three aims: to divide the tablet in two 
halves; to divide the tablet in equal dosages or to divide the tablet in order to ease the 
swallowing of it (and not to divide it into equal dosages). 
Throughout the development of the present work, several articles were analysed 
using mostly the PubMed database, the Google Scholar web search engine and 
keywords, such as “tablet subdivision”, “tablet splitting”, “breakability of tablets”, 
“scored tablets”, “splitability of tablets”, “crumbling” and “regulatory requirements”. 
The selected articles were published between 2002 and 2018. 
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3.1.2 Codification of the tablets 
 
The tablets used in the following assessments and experiment were kindly 
provided by a pharmaceutical company. They were selected, considering the presence 
of a score line and the number of units made available to perform the necessary 
pharmacotechnic tests and further assessment of the subdivision by the volunteers. 
They were then coded.  
The codification was based on characteristics of the tablets, as shown in Table 1. 
The first digit corresponds to the shape of the tablet, “0” meaning oblong and “1” 
meaning round; the second digit reflects the aim of the score, “0” being to ease the 
swallowing of the tablet, “1” to divide it in equal dosages and “2” if the purpose of the 
score is not mentioned or if it is not clear; the third digit reflects the number of scores 
in one side of the tablet (e.g. 1, 2, 3, …) and the fourth digit is either “1” or “2” if the 
tablet is scored in only one side or both sides, respectively. The last two digits 
correspond to the identification number (from 01 to 21). Number “06” was cut out as 
there were not enough tablets to perform the assessment. 
 
3.1.3 Characterisation of the tablets 
 
The third phase took place at the laboratory in the Faculty of Pharmacy, 
University of Lisbon. It consisted in performing some physical and pharmacotechnic 
tests in order to characterize the tablets as well to assess its compliance with the 
regulatory requirements. As such, the tablet resistance to crushing (also designated as 
tablet hardness), was measured by using an ERWEKA® TBH 20 Tablet Hardness 
Tester (Erweka, Germany). 
Then, the uniformity of mass test (Ph. Eur. 2.9.5) was performed. The assessment 
of the tablets splitability was performed upon weighing the whole tablets as well as 
the respective halves after splitting by using a AG204 Delta Range® scale (Mettler 
Toledo GmbH, Germany), coupled to a LC-P45 printer (Mettler Toledo GmbH, 
Germany).  In addition, the tablets dimensions (diameters, thickness and the depth of 
the score line) were measured by using a Fischer Darex® sliding caliper and recorded. 
In the case of oblong tablets, the larger and smaller diameters) were recorded.  
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3.1.4 Preparation of the sets given to the volunteers 
 
The succeeding step was to prepare the sets of tablets given to the volunteers 
to break. From the total of the twenty tablets only fifteen were used in the study, since 
some tablets presented such similarities that it would be redundant to use them as 
different observations. In addition, it was considered preferable to have a smaller 
number of different drug products but a larger number of observations per product 
than the other way round. 
In order to minimize the inter-subject variability due to the intrinsically 
subjective perception of the difficulty in breaking the tablets, each set of tablets to be 
split by subjects included tablets from a “hard to break” and “easy to break” products. 
Tablets from these two “standard” products were broken, by the subjects, before the 
“test” products and would hopefully work as perception references to the ease of 
breakability. 
The tablets chosen for each of the subjects was predetermined, prearranged and 
packed into individual plastic bags (Figure 2). as sets. In each of these given sets, 
tablets from four different drug products were provided, in a total of ten. A prediction 
model (9) helped to select these tablets, since it provided a prediction of which would 
be easier or more difficult for the subjects to break. Such prediction was important to 
classify the drug products according to the difficulty of breaking tablets and to 





Figure 2. Plastic bags used to pack the sets of tablet  
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Table 1. Codification of the tablets 














121101 Round (1) 2 1 1 01 
101102 Round (1) 0 1 1 02 
001203 Oblong (0) 0 1 2 03 
121104 Round (1) 2 1 1 04 
021105 Oblong (0) 2 1 1 05 
111207 Round (1) 1 1 2 07 
111208 Round (1) 1 1 2 08 
011109 Oblong (0) 1 1 1 09 
021010 Oblong (0) 2 1 0 10 
021111 Oblong (0) 2 1 1 11 
021112 Oblong (0) 2 1 1 12 
021113 Oblong (0) 2 1 1 13 
011214 Oblong (0) 1 1 2 14 
011215 Oblong (0) 1 1 2 15 
011116 Oblong (0) 1 1 1 16 
021217 Oblong (0) 2 1 2 17 
021118 Oblong (0) 2 1 1 18 
121119 Round (1) 2 1 1 19 
021220 Oblong (0) 2 1 2 20 





According to this model, in the case of round tablets, the physical parameters that 
shown to have a larger contribution to the ease of subdivision were: resistance to 
crushing, the diameter, the presence of a score mark that was either one-sided (“0”) or 
two-sided (“1”), the thickness and the shape, meaning if the tablet was either a 
biconvex tablet (“0”) or a flat tablet (“1”). In the case of oblong tablets, there were 
also parameters considered to be crucial for the ease of subdivision: the diameter, the 
depth of the score line, the diameter/width ratio and the resistance to crushing. 
However, the prediction model applied to oblong tablets, instead of having a formula 
as round tablets, each parameter had a cut off limit. In order to the ease of subdivision 
to be at least eighty percent, all parameters had to meet these acceptance criteria. 
Unfortunately, when applied to the tablets for this study, none of the tablets met all 
the criteria, therefore the prediction model was unable to provide enough information 
for the selection of standards from all the products available. In addition to the 
referred model, three non-trained volunteers classified the tablets regarding their 
perception of the ease of breakability. 
Subsequently, in each set given to the volunteer, two out of the four different 
tablets in each set were considered standards. One of the standards belonged to a 
group of three tablets - considered very difficult or almost impossible to break – them 
being 121104, 111208 and 011116. A second standard belonged to another group of 
tablets - considered easily breakable – them being 121101, 011203 and 021105. Each 
of the standards were repeated twice, making a total of four tablets (out of ten in 
total). The other two tablets from each set were chosen from a group of nine tablets, 
namely 101102, 111207, 011109, 021010, 021111, 021112, 021113, 011214, 011215, 
021217, 021118, 121119, 021220 and 121121. These two different tablets were 
repeated thrice, making a total of six tablets (out of ten in total).  
 
3.1.5 Study with volunteers  
 
The third phase consisted of the assessment of the ease of breakability by subjects 
(volunteers) as well as the weighing of the resulting tablets fractions. It was 
performed at a community pharmacy, in Castelo Branco, Portugal (Farmácia Ferrer, 
Lda.), in which volunteers meeting the inclusion criteria - elderly with a physical 
appearance corresponding to a person of not less than fifty-years old, with no apparent 
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handicap that would limit the ability to split the tablets -  were invited by the 
pharmacists or pharmacy technicians to participate in the study, and conducted to a 
separate room. In this room, a brief description of the aim of this project was given to 
the volunteers and they were asked to break, by hand, ten tablets as they would in 
their homes (without mechanical assistance (13)). No suggestion of breaking methods 
was provided, since it could bias the outcomes of the study.  The volunteers were also 
told that they would not, in any circumstances swallow the tablets after their splitting 
(as recommended in (5) – “Care should be taken that the panelist does not swallow the 
tablet before or after breaking”). 
The tablets were given to subjects in a predefined non-random sequence, as 
exemplified in Table 2. 
 
Table 2. Scheme of the sequence of subdivision for each set 
Number of tablet Type 
1 “Easy” Standard 1 
2 “Hard” Standard 1 
3 Test 1 
4 Test 2 
5 “Hard” Standard 1 
6 Test 2 
7 Test 1 
8 “Easy” Standard 1 
9 Test 1 
10 Test 2 
 
To meet the recommendation of using 30 tablets to assess the tablet subdivision 
(5)(11), 47 subjects were enrolled in the study.   
The volunteers were also asked to quantify their effort while breaking each of the 
tablets. To ease the level of breakability evaluation by the volunteer, an illustration 
was shown at the beginning of the experiment Figure 3. 
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Figure 3. Illustration created to ease the evaluation by the patient 
 
Each of the halves of the broken tablets or the whole tablet in case of failure to 
break were placed into numbered compartments of common weekly tablet organizers 
(Figure 4). These fractions, resulting from the tablets broken by the volunteers, were 
weighted by using a Sartorius ED153-PCE scale (Sartorius, Germany) to evaluate the 
fractions weight similarity as well as the loss of mass due to crumbles during the 




Figure 4. Weekly tablet organizers used to store tablets (whole and fragments) 
 
3.1.6 Data analysis 
 
Three different outcomes were recorded for each tablet break: 
a) the success in breaking the tablet (was the volunteer able/unable to break 
the tablet?) 
b) the level of difficulty, in breaking the tablet, reported by the volunteer 
c) the mass of all the fractions resulting from breaking the tablet 
 
The results were arranged and compiled into tables, for data analysis.  
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4 Results  
4.1 Characterisation of the tablets 
 
Two assessments were made previously to the study. The first was the 
measurement of tablet resistance to crushing (tablet hardness). Ten tablets of each of 
the twenty different tablets were measured. The average value as well as the range of  
tablet resistance to crushing of each tablet are shown in Table 3. 
Table 3. Tablet resistance to crushing (expressed in Newtons) 
 
Code Minimum value  Maximum value Average value 
121101 53 66 60 
101102 57 66 61 
001203 279 369 339 
121104 74 84 79 
021105 50 80 67 
111207 127 191 166 
111208 199 245 214 
011109 142 181 166 
021010 78 118 105 
021111 107 237 193 
021112 176  218 192 
021113 143 185 169 
011214 96  139 113 
011215 176  251 223 
011116 107  126 115 
021217 200  299 237 
021118 84  99 90 
121119 54  64 59 
021220 164  238 202 
121121 61  74 67 
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Combining the resistance to crushing to measured parameters - as diameter and 
thickness – and visual parameters – as score mark (one-sided or two-sided ) and shape 
(biconvex or flat) – it was possible to apply the prediction model to round tablets. 
(Table 4) 
Table 4. Prediction model applied to round tablets 
 
Legend: Score mark - 0 if one-sided, 1 if two-sided; Shape - 0 if biconvex, 1 if flat 
 
Combining the resistance to crushing to measured parameters - as diameter, width 
and depth of score line – it was possible to apply the prediction model to oblong 
tablets. (Table 5) 
Then, the whole tablets and their respective halves after splitting were weighted. 
Twenty tablets of each of the twenty different tablets were measured. The average 
whole tablet weight as well as the minimum and maximum values are shown in Table 
6 , and the tablet halves weight is shown in Table 7 (Halves A) and Table 8 (Halves 
B). It is also shown, in each of these tables, the deviation of the minimum and 
maximum values. Summarizing aspects of these tablets are shown in Table 9, namely 
the mass loss - obtained from the sum of the halves weight in comparison with the 
average whole tablet weight, and the deviation of the average weight of halves A in 
























121101 60 12,63 0 3,27 1 99  
101102 61 8,04 0 3,44 1 51  
121104 79 8,05 0 4,43 0 32  
111207 166 7,94 1 2,46 0 82  
111208 214 9,92 1 3,36 0 62  
121119 59 10,08 0 3,48 1 90  
121121 67 10,64 0 4,26 0 93  
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≥ 10 mm ≥ 2.0 
≥ 0.5 
mm 
≤ 100 N   
001203 13,11 2,53 0,37 339 ≤ 
0.800 
2/4 
021105 9,05 2,25 0,79 68 ≤ 
0.800 
3/4 
011109 12,17 1,98 0,83 166 ≤ 
0.800 
2/4 
021010 11,58 1,63 0,15 105 ≤ 
0.800 
1/4 
021111 10,20 1,97 0,27 193 ≤ 
0.800 
1/4 
021112 10,20 1,97 0,42 192 ≤ 
0.800 
1/4 
021113 10,26 1,98 0,38 169 ≤ 
0.800 
1/4 
011214 10,08 1,96 0,25 113 ≤ 
0.800 1/4 
011215 11,23 1,96 0,11 223 ≤ 
0.800 
1/4 
011116 10,10 1,99 0,17 115 ≤ 
0.800 1/4 
021217 11,27 1,96 0,09 237 ≤ 
0.800 
1/4 
021118 8,07 1,44 0,05 90 ≤ 
0.800 1/4 









Table 6. Whole tablet weight  
  
 Code Whole tablet weight Deviation  
AVG MIN MAX MIN (%) MAX(%) 
121101 483,76 474,4 491,9 -1,90 1,70 
101102 181,12 178,4 184,8 -1,50 2,00 
001203 272,22 265,2 278,3 -2,60 2,20 
121104 181,4 176,9 186,0 -2,50 2,50 
021105 91,32 89,8 92,2 -1,70 1,00 
111207 182,47 177,4 186,1 -2,80 2,00 
111208 365,77 360,6 369,4 -1,40 1,00 
011109 269,08 263,7 273,3 -2,00 1,60 
021010 243,86 239,9 246,2 -1,60 1,00 
021111 181,48 170,1 188,1 -6,30 3,60 
021112 184,39 181,5 186,5 -1,60 1,10 
021113 1814,2 177,8 183,8 -2,00 1,30 
011214 171,02 167,6 174,9 -2,00 2,30 
011215 170,57 166,7 173,4 -2,30 1,70 
011116 183,58 181,1 187,4 -1,40 2,10 
021217 170,27 164,3 175,2 -3,51 2,90 
021118 121,1 119,9 123,2 -0,99 1,73 
121119 324,16 322,1 326,5 -0,64 0,72 
021220 170,24 163,6 176,1 -3,90 3,40 
121121 402,17 394,1 408,7 -2,01 1,62 
 
Legend: AVG - Average value; MIN – Minimum value; MAX – Maximum Value. 



















Table 7. Tablet halves weight (Halves A)  
 
 Code Weight of Halve A Deviation 
 AVG MIN MAX MIN (%) MAX(%) 
121101 235,06 259,6 208,1 10,40 -11,50 
101102 90,73 85,8 94,6 -5,40 4,30 
001203 134,12 122,7 144,8 -8,50 8,00 
121104 89,78 70,9 108,3 -21,00 20,60 
021105 45,24 40,8 48,7 -9,80 7,60 
111207 92,36 88,6 96,7 -4,10 4,70 
111208 184,78 174,7 191,1 -5,50 3,40 
011109 140,61 128,0 156,3 -9,00 11,20 
021010 123,15 115,4 134,8 -6,30 9,50 
021111 87,56 79,8 99,7 -8,90 13,90 
021112 86,64 79,6 101,3 -8,10 16,90 
021113 83,89 72,4 97,5 -13,70 16,20 
011214 82,96 75,9 88,0 -8,50 6,10 
011215 84,91 77,6 90,5 -8,60 6,60 
011116 92,8 87,7 98,3 -5,50 5,90 
021217 83,28 47,1 11,19 -43,44 34,37 
021118 61,03 57,7 63,4 -5,46 3,88 
121119 145,74 109,4 168,8 -24,93 15,82 
021220 904,7 80,1 115,7 -91,10 -87,20 
121121 199,99 184,4 248,6 -7,80 24,31 
 
Legend: AVG - Average value; MIN – Minimum value; MAX – Maximum Value. 



















Table 8. Tablet halves weight (Halves B) 
 
 Code Weight of Halve B Deviation 
 AVG MIN MAX MIN (%) MAX(%) 
121101 247,96 274,9 223,4 10,90 -9,90 
101102 90,24 85,2 94,7 -5,60 4,90 
001203 137,95 126,1 148,9 -8,60 7,90 
121104 91,49 73,9 112,4 -19,20 22,90 
021105 46,06 43,0 50,0 -6,60 8,60 
111207 90,14 83,7 94,8 -7,10 5,20 
111208 180,88 175,3 190,7 -3,10 5,40 
011109 128,44 113,3 144,1 -11,80 12,20 
021010 122,16 110,3 129,6 -9,70 6,10 
021111 93,66 78,7 102,6 -16,00 9,50 
021112 97,67 84,8 104,6 -13,20 7,10 
021113 97,02 83,9 108,0 -13,50 11,30 
011214 87,17 82,2 91,5 -5,70 5,00 
011215 85,64 78,7 89,7 -8,10 4,70 
011116 90,36 83,4 95,1 -7,70 5,20 
021217 87,05 57,1 124,4 -34,41 42,91 
021118 60,62 57,3 64,4 -5,48 6,24 
121119 178,15 153,7 212,5 -13,72 19,28 
021220 79,86 53,3 86,9 -33,30 -8,80 
121121 202,19 153,0 214,7 -24,33 6,18 
 
Legend: AVG - Average value; MIN – Minimum value; MAX – Maximum Value. 























tablet weight  
AVG Weight 
of Halve A + 
AVG Weight  
of Halve B  
Mass loss (%) 
Deviation 
Halve A/ 
Halve B (%) Code 
121101 483,76 483,02 -0,15 -5,20 
101102 181,12 180,97 -0,08 0,50 
001203 272,22 272,07 -0,06 -2,80 
121104 181,4 181,27 -0,07 -1,90 
021105 91,32 91,3 -0,02 -1,80 
111207 182,47 182,5 0,02 2,50 
111208 365,77 365,66 -0,03 2,20 
011109 269,08 269,05 -0,01 9,50 
021010 243,86 245,31 0,59 0,80 
021111 181,48 181,22 -0,14 -6,50 
021112 184,39 184,31 -0,04 -11,30 
021113 181,42 180,91 -0,28 -13,50 
011214 171,02 170,13 -0,52 -4,80 
011215 170,57 170,55 -0,01 -0,90 
011116 183,58 183,16 -0,23 2,70 
021217 170,27 170,33 0,04 -4,33 
021118 121,1 121,65 0,45 0,68 
121119 324,16 323,89 -0,08 -18,19 
021220 170,24 170,33 0,05 13,30 
121121 402,17 402,18 0,00 -1,09 
 


















4.2 Breakability assessment study 
 
This study had a total of 47 participants, each of them breaking a total of ten 
tablets. Therefore, there was a total of 470 observations. 
4.2.1 Ability to break the tablets 
 
Out of the 470 observations, a total of 42 tablets were not broken. This means 
that volunteers were not able to break 8,94% of all the tablets that volunteers tried to 
break. 
Out of the 15 tablets in the study, 5 of them belonged to this group of tablets that 
were not broken by the volunteers. Tablets with the codes 121104, 111208 and 
011116, belonged to the “Hard” Standards, which means that volunteers were not able 
to break 7,87% of the “Hard” Standards. The other tablets – 121121 and 101102 
belonged to the test tablets group. Results are shown in Table 10. 
 
Table 10. Tablets that volunteers were not able to break  
 
Code Occurences 
Occurences of “Hard” 
Standards Tablets 
101102 3 - 
121104 18 18 
111208 16 16 
011116 3 3 
121121 2 - 
Total  42 37 
 
4.2.2 Mass loss 
 
After the volunteers broke the tablets that were given to them, both of the halves 
of each tablet were weighted. Both weights of each tablet were summed, obtaining the 
mass that was not lost due to powdering or crumbling, shown in Table 11. 
 The deviation of this value in comparison to the average mass - previously 
calculated in Table 6 - is shown in  Table 12. A limit of 5% of mass loss was 
adopted.  
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 AVG MIN MAX AVG MIN MAX AVG MIN MAX 
121101 244,5 157 283 237,2 208 318 481,7 451 495 
101102 89,3 41 140 83,8 17 97 173,1 124 186 
001203 138,8 123 167 132,4 101 151 271,1 263 281 
121104 95,1 78 112 83,2 55 107 178,3 162 186 
021105 46,7 37 60 44,7 31 52 91,4 88 95 
111208 182,4 174 193 180,2 146 191 362,6 339 370 
011109 136,5 123 148 134,6 124 151 271,1 260 278 
021010 126,2 95 144 120,6 87 140 246,8 182 256 
021111 92,5 82 104 89,6 78 103 182,0 168 188 
011214 84,2 77 91 85,9 76 101 170,1 158 186 
011116 91,7 83 104 91,4 80 101 183,2 178 188 
021118 59,7 44 71 64,2 51 82 123,9 117 130 
121119 162,6 125 195 159,4 84 197 322,0 228 333 
021220 86,2 67 94 86,2 79 103 172,4 168 180 
121121 200,5 176 241 200,9 137 227 401,5 378 408 
 
Legend: AVG - Average value; MIN – Minimum value; MAX – Maximum Value. 




















Table 12. Mass loss 
 
Legend: AVG - Average value; MIN – Minimum value; MAX – Maximum Value. 

























 AVG MIN MAX AVG MIN MAX AVG MIN MAX 
121101 50,5 32,5 58,5  49,0  43,0  65,7  99,6  93,2  102,3  
101102 49,3 22,6  77,3  46,3  9,4  53,6  95,6  68,5  102,7  
001203 51,0 45,2  61,3  48,6  37,1  55,5  99,6  96,6  103,2  
121104 52,4  43,0  61,7  45,9  30,3  59,0  98,3  89,3  102,5  
021105 51,1  40,5  65,7  48,9  33,9  56,9  100,1  96,4  104,0  
111208 49,9  47,6  52,8  49,3  39,9  52,2  99,1  92,7  101,2  
011109 50,7  45,7  55,0  50,0  46,1  56,1  100,8  96,6  103,3  
021010 51,7  39,0  59,1  49,5  35,7  57,4  101,2  74,6  105,0  
021111 50,9  45,2  57,3  49,4  43,0  56,8  100,3  92,6  103,6  
011214 49,3  45,0  53,2  50,2  44,4  59,1  99,5  92,4  108,8  
011116 50,0  45,2  56,7  49,8  43,6  55,0  99,8  97,0  102,4  
021118 49,3  36,3  58,6  53,0  42,1  67,7  102,3  96,6  107,3  
121119 50,2  38,6  60,2  49,2  25,9  60,8  99,3  70,3  102,7  
021220 50,6  39,4  55,2  50,6  46,4  60,5  101,3  98,7  105,7  
121121 49,9  43,8  59,9  50,0  34,1  56,4  99,8  94,0  101,4  
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4.2.3 Non compliances 
 
Out of the 470 observations, a total of 6 tablets split in more than 2 fragments, 
which represents a total of 1,28% of all the tablets that volunteers tried to break. 
Results are shown in Table 13. 
 









4.2.4 Ease of subdivision 
 
It was asked that the volunteers quantify their effort whilst breaking each of the 
tablets that were given to them. In case of the tablets that the volunteers were able to 
break the tablet, the score could be “1” if it was very hard for the volunteers to break 
the tablet;  “2” if it was relatively difficult; “3” if it was relatively easy; and “4” if it 
was very easy to break the tablet. The results are shown in Table 14 . An average of 
the  answers given by volunteers for each tablet is shown in Table 15. 
 
Table 14. Answers of the volunteers regarding ease of subdivision 
 
Score Number of Answers Percentage (%) 
“1” 25 5,32  
“2” 32 6,81  
“3” 135 28,72  
“4” 236 50,21  













































































4.3 Crossover data 
 
4.3.1 Broken tablets – Model prediction and experimental observations 
 
In this section, a comparison between the prediction of the model (regarding how 
many volunteers would be able to break the tablets) and what actually occurred in the 
assessment of breakability study (percentage of broken tablets and an average value of 
the score volunteers attributed to the ease of breakability) is made. Results in Table 
16 apply to round tablets and results in Table 17 apply to oblong tablets. 
 
Table 16. Volunteers ability to break round tablets and their perception 
 
 

























score (AVG)   
121101 99  100,00  3,63 
101102 51  93,33  2,96 
121104 32  43,75  1,71 
111208 62  46,67  1,43 
121119 90  100,00  3,52 
121121 93  93,94  3,77 
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Table 17. Volunteers ability to break oblong tablets and their perception  
 
 
Legend: AVG - Average value. 
 
4.3.2 Ease of subdivision versus Resistance to Crushing 
 
In Table 18 a comparison between the average value of the score volunteers 
attributed to the ease of breakability of tablets and the resistance to crushing (average 
value) is done. It is possible to compare these values according to the group of tablets 






 Model prediction Breakability assessment study 






score (AVG)   
001203 ≤ 0.800 2/4 100,00  3,69 
021105 ≤ 0.800 3/4 100,00  3,53 
011109 ≤ 0.800 2/4 100,00  3,77 
021010 ≤ 0.800 1/4 100,00  3,67 
021111 ≤ 0.800 1/4 100,00  3,73 
011214 ≤ 0.800 1/4 100,00  3,67 
011116 ≤ 0.800 1/4 90,63   2,59 
021118 ≤ 0.800 1/4 100,00  2,83 
021220 ≤ 0.800 2/4 100,00  3,76 
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Table 18. Ease of subdivision versus resistance to crushing 
 
 





4.3.3 Mass deviation – Assessments of Mass uniformity versus breakability 
study  
 
In Table 19 it is done a comparison between the results previous to the 
breakability assessment study, done in the faculty laboratory and the results from the 
study in the community pharmacy. These results represent the mass deviation of the 
whole tablets and the sum of their halves to the same value (average mass of each 



















121101 Round 3,63 60 
001203 Oblong 3,69 339  
021105 Oblong 3,53 67 
“Hard” 
Standards 
121104 Round 1,71 79  
111208 Round 1,43 214 
011116 Oblong 2,59 115 
Test 
Tablets 
101102 Round 2,96 61 
011109 Oblong 3,77 166 
021010 Oblong 3,67 106 
021111 Oblong 3,73 193 
011214 Oblong 3,67 113 
021118 Oblong 2,83 90 
121119 Round 3,52 59 
021220 Oblong 3,76 202 
121121 Round 3,77 67 
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Table 19. Mass deviations 
 
 
Assessment of mass uniformity 
(faculty laboratory) 
Breakability assessment study 
(pharmacy laboratory) 














121101 48,59 51,26 99,85 50,5 49,0 99,6 
101102 50,09 49,82 99,92 49,3 46,3 95,6 
001203 49,27 50,68 99,94 51,0 48,6 99,6 
121104 49,49 50,44 99,93 52,4 45,9 98,3 
021105 49,54 50,44 99,98 51,1 48,9 100,1 
111208 50,52 49,45 99,97 49,9 49,3 99,1 
011109 52,26 47,73 99,99 50,7 50,0 100,8 
021010 50,50 50,09 100,59 51,7 49,5 101,2 
021111 48,25 51,61 99,86 50,9 49,4 100,3 
011214 48,51 50,97 99,48 49,3 50,2 99,5 
011116 50,55 49,22 99,77 50,0 49,8 99,8 
021118 50,40 50,06 100,45 49,3 53,0 102,3 
121119 44,96 54,96 99,92 50,2 49,2 99,3 
021220 53,14 46,91 100,05 50,6 50,6 101,3 
121121 49,73 50,27 100,00 49,9 50,0 99,8 
 








101102 121104 111208 11116 121121
5 Discussion 
 
Out of the 470 observations of the breakability assessment study, some tablets 
were not broken (Table 10) or were broken but in more than two fragments (Table 
13).  
Overall, the volunteers were not able to break a total of 8,94% of the tablets (as 
shown in Figure 5), which is a quite significant amount of scored tablets that part of a 
the population probably wo not be able to break. From these tablets, 7,87% were from 




























Figure 6. “Hard” standard tablets that volunteers were not able to break 
 
These three “standards” are also the three tablets with the three lower scores in 
terms of perception of ease of breakability from the volunteers (shown in Table 15). 
Also, from these, 121104 and 111208 had a higher expression of non-broken tablets 
than 011116, and 011116 had a significant higher score regarding its ease of 
breakability, which supports the fact that these were the tablets with such findings.   
Regarding the other two tablets, 121121 and 101102 (test tablets), two distinct 
situations occurred: 
a) Two different volunteers (A and B, as shown in Figure 7) were not able 
to break tablet 101102. In both of them it corresponded to the second 
101102 tablet out of three  that were in their respective sets. Both were not 
able to break their respective “hard” standards tablets included in his sets 
(One had tablet 111208 and the other  had tablet 011116). This probably 
means that the reason for both volunteers not to be able to break tablet 
101102  is a patient-related cause. Nevertheless this situation has to be 
foreseen and  therefore preventive measures should be taken by  
manufacturers. 
b) A third volunteer (C, as shown in Figure 7) was not able to break two out 
of three tablets 121121 (second and third in the set); this volunteer also 
was not able to break the first out of three 101102 tablets, and the other 






able to break the respective “hard” standard tablets included in the given 




Figure 7. Examples of volunteers outcomes 
Legend: ✔️- tablet was broken by the volunteer; × - tablet was not broken by the 
volunteer; F – tablet was fragmented in more than the two expected fragments. 
 
From the tablets that broke into more than two fragments (Table 13), the most 
occurrences were with tablet 101102, two of which were the case of the above 
referred volunteer (C, as shown in Figure 7). This volunteer was not able to break a 
total of five tablets (four prior to the two non compliances and one afterwards). The 
other occurrence of this non compliance with tablet 101102 was by a volunteer that 
could not break both two tablets 111208 given in his set. Since 111208 is a “hard” 
standard, a possible cause could be that the effort that the volunteer had to apply to 
“hard” standards tablets was of such intensity that when applied the same amount of 
effort into tablet 101102 - which has one of the lowest values of resistance to crushing 
(61 N) - it broke in more than two fragments, which should not happen in any 
circumstances. This supposition might apply as well to the situation above. 
The other three tablets that broke in more than two fragments were 121101, 
121104 and 121119, each of them by different volunteers, that were all able to break 
the “hard” standards tablets given in their sets. 
 In conclusion, a total of six tablets out of the 470 observations broke in more 
than two fragments, representing 1,28% (proportion of the tablets shown in ). This 
value in addition to the tablets that were not broken, sums up to a significant total of 





Figure 8. Proportion of tablets that broke in more than two fragments 
 
In Table 14 the scores that volunteers attributed according to their perception of 
effort while breaking each tablet are grouped. This data (graphic representation shown 
in Figure 9) allows to conclude that: 
a) around a third (28,72%) answered that the tablets were relatively easy and 
that around half (50,21%) of the volunteers answered that that the tablets 
were very easy to break. These findings sugest that the the test group 
tablets (60%) and “easy” standards (20%), should be distributed in these 
two categories (relatively or very easy to break) 
b) and that around a fifth (21,07%) of the volunteers answered that either the 
tablets were difficult (6,81%), very difficult (5,32%) or that they were not 





















Figure 9. Score attributed by the volunteers 
Data in Table 15Ease of subdivision score support these findings since the “hard” 
standard have the three lowest scores regarding the ease of subdivision, and that 
“easy” standards have similar scores to the highest scored “test” groups. Additionally, 
the average score of the ease of subdivision of tablets 121119, 101102 and 021118 is 
the lowest out of the test and “easy” standards, suggesting that these are the tablets 
that were considered somewhat difficult to break. Therefore, the group that represents 
a fifth of the results might be formed not only by the tablets that volunteers were not 
able to break but also  by the three “hard” standards and these three tablets (121119, 
101102 and 021118)  – the six with the lowest attributed score  regarding the ease of 
subdivision.  
The ability to forecast of the prediction model is compared to what occurred in 
the breakability assessment study. In Table 16 the results are in respect to round 
tablets. The model predicted that tablets 121101, 121119 and 121121 would be the 
tablets that a larger number of subjects would be able to break. This prediction 
corresponds to the three round tablets with higher percentage of broken tablets in the 
study and it is also coherent to the finding regarding the score attributed  (by the 
volunteers) to the ease of subdivision of such tablets. Also, tablet 121104, which had 
the lowest predicted percentage of subjects that could break the tablets is also the 
tablet with the lowest percentage of broken tablets in the study. In Table 17 
(regarding oblong tablets), the scenario is different since the model had an “all-or-
nothing” criteria. Nevertheless, the criteria that the tablets fraction of criteria that the 







tablets met can be used as a comparative parameter. The tablet that fewer volunteers 
were able to break was tablet 011116, which only met one of the criteria and has the 
smaller score attributed  (by the volunteers) regarding ease of subdivision. 
In Table 18 the average breakability value (given by the volunteers) is allied to 
the average resistance to crushing of the tablets. Also, tablets are tagged regarding its 
shape (if they are round or oblong tablets). 
The three tablets that present lowest breakability scores -1,71; 1,43; and 2,59 - are 
also the tablets considered the “hard” standards - 121104, 111208 and 011116, 
respectively.  These findings are coherent with two tablets regarding their resistance 
to crushing, since 111208 has the second highest value (214 N) and 011116 the sixth 
highest value (115 N).  Tablet 121104 has a lower resistance value (79 N) so the 
physical hardness of this tablet is probably not the major factor for its difficulty in 
subdivision. For instance, it could be due to its very shallow depth of the score line 
and the fact that it is one sided. 
 Another finding regarding  these results is that five (121101, 101102, 121104, 
121119, 121121) out of the six round tablets have the five lowest resistance to 
crushing values (60 N, 61 N, 79 N, 59 N and 67 N, respectively). Despite this fact, 
only number 121121 has a higher score, the highest out of all the tablets (and the same 
as 011109). Therefore we can not imply that the shape of the tablet has an effect on 
the ease of breakability, even though the three tablets with the higher score are round 
(121121, 011109 and 021220).  
In the mass uniformity assessment phase, occurred in the laboratory of the 
Faculty of Pharmacy, University of Lisbon, twenty tablets of each of the available 
products were tested, both the whole tablets and their respective halves. Results are 
shown in Table 6 to Table 9.  
Regarding halves A (Table 7), tablets 121104, 021112, 021113 and 021220 
showed important deviations, of more than 15% according to the Ph. Eur. 9.2.5 
(regarding the minimum and maximum values) from the average mass. From these 
tablets  121104 and 021220 were selected to do the study with the volunteers. 
Regarding halves B (Table 8), tablets 021111 and 021220 also showed the same 
important deviations, from the average mass. Both these tablets were selected to do 
the study with the volunteers. These findings should predict what would occur in the 
breakability assessment study. 
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From these tablets, tablet 021220 has one of the largest deviation between halve 
A and halve B, (alongside with 121119) which should also predict what would occur 
in the breakability assessment study, regarding inequity of both halves after splitting. 
In Table 19 it is presented, in percentage, the mass deviations from the previous 
established average tablet weight (second column in Table 6), both from the results 
during the assessment of mass uniformity (that occurred in a laboratory from the 
faculty) as the results during the breakability assessment study (that occurred in the 
community pharmacy). In the first study only one subject broke all the tablets, with 
only two different methods. In the case of flat tablets, the subject held the tablet 
between fingers and applied pressure downwards. In the case of convex tablets, the 
subject applied pressure downwards, pushing towards a surface with only the aid of 
thumbs.  In the second study, a total of 47 different volunteers broke different tablets, 
with no indication of the method they should use (only that they could only use their 
hands, with no mechanical assistance (13)), therefore a few of methods were applied 
to subdivide the tablets. Given these facts, some differences were expected to occur 
regarding the accuracy of subdivision.  
A comparison between the columns of Table 19 regarding the halves can be done 
to predict which of the tablets would have a less accurate subdivision. For example, 
looking at the results of the halves (mass uniformity results): 
a) tablet 011109 presents a deviation of 47,73% (Halve B), which means less 
2,27% of mass than what it was expected;  
b) tablet 021220 presents a deviation of 46,91% (Halve B), which means less 
3,09% of mass than what it was expected; 
c) and tablet 121119 presents a deviation of 44,96% (Halve A), which means 
less 5,04% of mass than what it was expected. 
These are important findings because even if the sum of the halves do not have a 
representative mass loss, the halves do, and therefore a discrepancy in content in 
terms of the active substance can occur, therefore causing dose fluctuations for the 
patient. Now looking at the results of the halves (breakability assessment test), tablet 
101102 presents deviations of 49,4% (Halves A) and 46,3% (Halves B). Not only 
does the 46,3% value represent a mass loss of 3,7% of that halve, but also the sum of 
these percentages represent a total of 4,4% of total mass loss. This fact is consistent 
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with the results in Table 13 since tablet 101102 was the tablet presented most of the 
cases where the tablet broke in more than two fragments (instead of two halves). 
It is also interesting to see that the three tablets that suffered less variation 
(021010, 021118 and 021220, in decreasing order) in the mass uniformity assessment 
are the same as in the faculty (021118, 021220 and 021010, in decreasing order). 
Since the products that were provided for the study were generic products, a 
research was done in order to find out to detect any discrepancies between the SmPC 
and PIL of these generic products and the SmPC and PIL of the reference drug. This 
was proven to be true since some reference drugs presented score lines with a 
different purpose than the generic product, which should not occur since they should 
present consistent scoring purposes. In second place, the product leaflets that came 
with the provided boxes - which were all within the expiration date - did not match 
the majority of the online documents (19), which means that updates to the SmPC and 
the PIL were made but products are commercialized with outdated information. Also, 
in some cases, differences regarding the purpose of the score line were detected 
between the SmPC and the PIL, which suggests that sometimes patients do not get the 
same information about the suitability of the score line as healthcare professionals do. 
Moreover, concerning labelling, the intended function of score lines should be 
stated in the SmPC or the (PIL), e.g. the mentioning of “functional scoring” (1) as 
well as the intended dose after splitting, because basing that interpretation on 
posology schemes might be subjective. Also, there should not be misleading 
characteristics (e.g. bisected (1)). It is purposed that standard quotes are included in 
the labelling  (“The score line is only to facilitate breaking for ease of swallowing and 
not to divide into equal doses.”, “The tablet can be divided into equal halves.” and 
“The tablet should not be divided.” (15)). A pictorial information regarding the 
method that is advised to split the tablet should also be included in labelling (as shown 
in Figure 1, retrieved from (10)). Finally, there should be a concern about 
transmitting information regarding storage conditions after splitting (e.g. the period of 
time that ensures safety of the split tablets and atmospheric conditions). 
Since some discrepancies can occur between the content of each halve of tablets 
after they are split, assessments should ensure safety regarding the subdivision of 
tablets, based on aspects of subdivision of tablets should be assessed, namely the 
“accuracy of subdivision”, “loss of mass” and the “ease of subdivision” (as advised 
in) (5). These assessments should be done not only on the pharmaceutical 
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development (e.g. manufacturing scale-up processes, changes regarding excipients 





















The present study has examined if products marketed in Portugal are in 
compliance with regulatory requirements, regarding the subdivision of tablets. 
A comprehensive review was made regarding regulatory requirements and 
available guidance documents concerning this subject, published in the last seventeen 
years. Even though a lot of important concerns have been raised, not all of them are 
actually implemented in a mandatory and legal manner. This is considered to be of 
extreme relevance since more strict criteria would allow less non conformities, and 
therefore more safety for the patient regarding the usage of scored tablets. For 
instance, in this study, 10,22% of the observations reflect either the inability of the 
volunteers to break the tablets or the splitting of tablets in more fragments than the 
two expected halves.  
Further findings of this study showed that around half of the observations 
correspond to situations in which the patients classified the tablets as very easy to 
break. However, a fifth of the observations represent situations where the patients 
found the tablets hard or very hard  to break as well as cases where the patient was not 
able to break the tablet.  
The usage of a prediction models showed to be a valuable asset in order to 
determine which tablet physical and pharmacotechnic parameters should be optimized 
for an enhanced and accurate tablet subdivision.  
New pharmaceutical approaches could be explored to minimize the effects of 
inaccurate tablet splitting, for instance, providing individual tablet cutters with the 
medicines or the usage of illustrations in product labelling to ensure an easy and even 
subdivision, as well as more information about the purpose of the score line 
A limitation of this study was that the provided products to do the assessments 
might not represent the overall variety of marketed tablets with score lines. 
Furthermore, it would be interesting to compare reference drugs instead of only 
 53 
generic products. However, the findings of the breakability assessment study that was 
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